Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
NPJ Breast Cancer
.
2023 Mar 16;9(1):14.
doi: 10.1038/s41523-023-00515-4.
Authors
Elisa Agostinetto
1
,
Evandro de Azambuja
1
,
Matteo Lambertini
2
3
Affiliations
1
Institut Jules Bordet and l'Université Libre de Bruxelles, Brussels, Belgium.
2
Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy. matteo.lambertini@unige.it.
3
Department of Medical Oncology, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy. matteo.lambertini@unige.it.
PMID:
36928216
PMCID:
PMC10020562
DOI:
10.1038/s41523-023-00515-4
No abstract available
Publication types
Letter